863 839

Cited 0 times in

SGLT2 억제제의 심혈관 질환에 대한 임상연구 결과와 심장 보호효과의 가능한 기전

DC Field Value Language
dc.contributor.author강은석-
dc.contributor.author조용인-
dc.date.accessioned2018-08-28T17:26:18Z-
dc.date.available2018-08-28T17:26:18Z-
dc.date.issued2018-
dc.identifier.issn2287-2892-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/162609-
dc.description.abstractPatients with type 2 diabetes (T2D) have a significantly higher risk of developing cardiovascular diseases such as myocardial infarction, heart failure, and stroke. Current anti-diabetic drugs are highly effective for managing hyperglycemia. However, most T2D patients are still at high risk for cardiovascular disease. Over the past decade, many studies have assessed the efficacy of anti-diabetic drugs in regards to cardiovascular disease outcomes in T2D patients. However, despite the effective glycemic control of these drugs, they failed to show significant benefits that impact the morbidity and mortality of cardiovascular disease (CVD). In recent years, anti-diabetic drugs, developed with other mechanisms, have shown significant results for improving the risk of CVD. In addition, sodium glucose cotransporter 2 inhibitors have shown promising results that impact CVD outcomes in several trials. This article will review the cardiovascular outcomes and possible cardioprotective mechanisms of sodium glucose cotransporter 2 inhibitors.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageKorean-
dc.publisher한국지질동맥경화학회-
dc.relation.isPartOfJournal of Lipid and Atherosclerosis-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleSGLT2 억제제의 심혈관 질환에 대한 임상연구 결과와 심장 보호효과의 가능한 기전-
dc.title.alternativeCardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitor and Its Possible Cardioprotective Mechanism-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthor조용인-
dc.contributor.googleauthor강은석-
dc.identifier.doi10.12997/jla.2018.7.1.21-
dc.contributor.localIdA00068-
dc.contributor.localIdA03866-
dc.relation.journalcodeJ01562-
dc.identifier.eissn2288-2561-
dc.subject.keywordSodium-glucose co transporter 2 inhibitors-
dc.subject.keywordCardiovascular outcome-
dc.subject.keywordCardioprotective mechanism-
dc.contributor.alternativeNameKang, Eun Seok-
dc.contributor.alternativeNameCho, Yong In-
dc.contributor.affiliatedAuthorKang, Eun Seok-
dc.contributor.affiliatedAuthorCho, Yong In-
dc.citation.volume7-
dc.citation.number1-
dc.citation.startPage21-
dc.citation.endPage31-
dc.identifier.bibliographicCitationJournal of Lipid and Atherosclerosis, Vol.7(1) : 21-31, 2018-
dc.identifier.rimsid60189-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.